Since the emergence of a new coronavirus, SARS-CoV-2, in China, there has been an unprecedented need to quickly develop an effective vaccine in light of the pandemic that was declared by WHO on March 11, 2020. Because research with related coronavirus vaccines had surfaced a syndrome of disease enhancement following virus challenge of animals immunized with some vaccine constructs, this quickly became a potential safety concern for new vaccine candidates against COVID-19, the disease caused by SARS-CoV-2. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This Meeting Report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.
This deliverable collates into a single document the SPEAC Spontaneous Abortion and Ectopic Pregnancy resources, including the I...
